CD33 and acute myeloid leukemia: A phase I (NCT03126864) trial enrolling adult and pediatric patients with r/r AML, terminated in October 2019; it investigated the safety and tolerability of three different doses of autologous CAR-T cells, modified to express CD33-targetedCAR-T cells [75].